The effect of chronic administration of buspirone on 6-hydroxydopamine-induced catalepsy in rats

Advanced Pharmaceutical Bulletin

Volumn 2, Issue 1, 2012, Pages 127-131

  Sharifi, Hamdolah ^a   Nayebi, Alireza Mohajjel ^a   Farajnia, Safar ^a  

^a UNIVERSITY OF TABRIZ   (Iran)

Author keywords

6 hydroxydopamine; Buspirone; Catalepsy; Chronic; Rat

Indexed keywords

1 (2 METHOXYPHENYL) 4 (4 PHTHALIMIDOBUTYL)PIPERAZINE; BUSPIRONE; OXIDOPAMINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CATALEPSY; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; MALE; NONHUMAN; RAT; SUBSTANTIA NIGRA PARS COMPACTA;

EID: 84875912260     PISSN: 22285881     EISSN: 22517308     Source Type: Journal    
DOI: 10.5681/apb.2012.019     Document Type: Article

References (22)

1. Neha Singh, Viness Pillay, Yahya E. Choonara Advances in the treatment of Parkinson's disease. Progress in Neurobiology 2007; 81:29-44.
2. Alireza M. Nayebi, Siyamak R. Rad, Mehdi Saberian, Saeid Azimzadeh, Morteza Samini. Buspirone improves 6-hydroxydopamine-induced catalepsy through stimulation of nigral 5-HT1A receptors in rats. Pharmacological reports 2010; 62:258-264.
3. Malú G, Tansey Melissa K. McCoy, Tamy C, Frank-Cannon. Neuroinflammatory mechanisms in Parkinson's disease: Potential environmental triggers, pathways, and targets for early therapeutic intervention.Experimental Neurology 2007; 208:1-25.
4. Malú G, Tansey Matthew S. Goldberg. Neuroinflammation in Parkinson's disease: Its role in neuronal death and implications for therapeutic intervention. Neurobiology of Disease 2010; 37:510-518.
5. Susan H. Fox Rosalind Chuang, Jonathan M. Brotchie JM. Parkinson's disease - opportunities for novel therapeutics to reduce the problems of levodopa therapy. Progress in Brain Research 2008;172: 479-494.
6. Schapira AH, Bezard E, Brotchie J, Calon F, Collingridge GL, Ferger B, et al. Novel pharmacological targets for the treatment of Parkinson's disease. Nature reviews Drug discovery. 2006;5(10):845-54.
7. Di Matteo V, Pierucci M, Esposito E, Crescimanno G, Benigno A, Di Giovanni G.Serotonin modulation of the basal ganglia circuitry: therapeutic implication for Parkinson's disease and other motor disorders. Prog Brain Res 2008; 172:423-463.
8. Fox SH, Chuang R, Brotchie JM. Serotonin and Parkinson's disease: On movement, mood, and madness. Movement disorders: official journal of the Movement Disorder Society. 2009;24(9):1255-66.
9. Nobuaki Egashira, Tomomi Matsuda, Emi Koushi, Kenichi Mishima, Katsunori Iwasaki, Yukihiro Shoyama, Michihiro Fujiwara. Involvement of 5-hydroxytryptamine1A receptors in Δ9-tetrahydrocannabinol-induced catalepsy-like immobilization in mice. European Journal of Pharmacology 2006;550:117-122.
10. Laurence Mignon, William A Wolf. Postsynaptic 5-HT1A receptor stimulation increases motor activity in the 6-hydroxydopamine-lesioned rat: implications for treating Parkinson's disease. Psychopharmacology 2007; 192: 49-59.
11. Mohajjel Nayebi A, Sheidaei H. Buspirone improves haloperidol-induced Parkinson disease in mice through 5-HT1A receptors. DARU 2010; 18:41-45.
12. B Scholtissen, F R J Verhey, H W M Steinbusch, A F G Leentjens. Serotonergic mechanisms in Parkinson's disease: opposing results from preclinical and clinical data. J Neural Transm 2006;113: 59-73.
13. A G Dhavalshankh, S A Jadhav, R V Gaikwad, R K Gaonkar, V M Thorat, JJ Balsara.Effects of buspirone on dopamine dependent behaviours in rats.Indian J Physiol Pharmacol 2007; 51 (4): 375-386.
14. S A Jadhav,R V Gaikwad, R K Gaonkar, V M Thorat, S C Gursale,J J Balsara. Dose-Dependent response of central dopaminergic systems to buspirone in mice..Indian Journal of Experimental Biology 2008;46:704-714.
15. Arturo Zazpe, Inés Artaiz, Ana Innerárity, Elena del Olmo, Elena Castro, Luis Labeaga, Angel Pazos, Aurelio Orjales. In vitro and in vivo characterization of F-97013-GD, a partial 5-HT1A agonist with antipsychotic- and antiparkinsonian-like properties. Neuropharmacology 2006;51: 129-140.
16. Ichikawa J, Meltzer HY. R(+)-8-OH-DPAT, a serotonin 1A receptor agonist, potentiated S(-)-sulpirideinduced dopamine release in rat medial prefrontal cortex and nucleus accumbens but not striatum. J Pharmacol Exp Ther1999; 291:1227-1232.
17. Harrington MA, Oksenberg D, Peroutka SJ. 5-Hydroxytryptamine 1Areceptors are linked to a Gi-adenylate cyclase complex in rat hippocampus. Eur. J Pharmacol 1988; 154:95-98.
18. Darakhshan Jabeen Haleema, Erum Shireena, M.A. Haleem. Somatodendritic and postsynaptic serotonin-1A receptors in the attenuation of haloperidol-induced catalepsy. Progress in Neuro-Psychopharmacology & Biological Psychiatry 2004;28:1323-1329.
19. Gower AJ, Tricklebank MD. Alpha 2-adrenoceptor antagonist activity may account for the effects of buspirone in an anticonfilict test in the rat. Eur J Pharmacol 1988; 155:129-137.
20. Kazuo Matsubaraa,, Keiko Shimizub, Manabu Sunoa, Kento Ogawab, Toshio Awayaa, Takehiro Yamadaa, Toshihiro Nodaa, Machiko Satomia, Ko-ichi Ohtakia, Kaoru Chibaa, Yoshikazu Tasakia, Hiroshi Shionob. Tandospirone, a 5-HT1A agonist, ameliorates movement disorder via non-dopaminergic systems in rats with unilateral 6-hydroxydopamine-generated lesions. Brain Research 2006; 1112:126-133.
21. Kristin B Dupre, Karen L Eskow, Christopher J Barnum, Christopher Bishop.Striatal 5-HT1A receptor stimulation reduces D1 receptor-induced dyskinesia and improves movement in the hemiparkinsonian rat. Neuropharmacology 2008; 55: 1321-1328.
22. Kristin B. Dupre Karen L Eskow, Giselle Negron, Christopher Bishop. The differential effects of 5-HT1A receptor stimulation on dopamine receptor-mediated abnormal involuntary movements and rotations in the primed hemiparkinsonian rat. Brain Research. 2007; 1158:135-143.